ARHGEF39: A Potential Drug Target and Biomarker (G84904)

Target Name: ARHGEF39

NCBI ID: G84904

ARHGEF39

ARHGEF39: A Potential Drug Target and Biomarker

ARHGEF39 (Rho guanine nucleotide exchange factor 39) is a protein that plays a critical role in the regulation of cell signaling pathways, including the G-protein-coupled receptor (GPCR) signaling pathway. GPCR signaling is a highly conserved pathway that is involved in various physiological processes in the cell, including sensory perception, neurotransmission, and hormone signaling. The deregulation of GPCR signaling has been implicated in various diseases, including cancer, neurodegenerative diseases, and behavioral disorders. Therefore, the identification of potential drug targets and biomarkers for GPCR signaling pathways is of great interest.

ARHGEF39: Structure and Function

The ARHGEF39 protein is a 21-kDa protein that belongs to the ARHGEF family of proteins. The ARHGEF family is characterized by the presence of a G-protein-coupled receptor-associated protein (GRP) domain and a nucleotide-exchange factor (NEXF) domain. The GRP domain is responsible for interacting with the GPCR and the NEXF domain is responsible for interacting with the nucleotides in the GPCR.

ARHGEF39 is involved in the regulation of GPCR signaling by activating the activity of the ARHGEF40 protein. ARHGEF40 is a protein that contains a nucleotide-exchange factor (NEF) domain and is responsible for regulating the activity of ARHGEF39. The NEF domain of ARHGEF40 is in close proximity to the GPCR and allows it to interact with the protein and regulate its activity.

The ARHGEF39 gene is located on chromosome 12q22 and has been implicated in the development and progression of various diseases, including cancer. The expression of ARHGEF39 has been shown to be associated with the GPCR signaling pathway and has been implicated in the regulation of neurotransmission, including the regulation of synaptic plasticity and the modulation of neuronal excitability.

ARHGEF39 as a drug target

The identification of ARHGEF39 as a potential drug target is based on its involvement in the regulation of GPCR signaling pathway and its association with various diseases. The development of small molecules that can modulate the activity of ARHGEF39 may provide new therapeutic options for the treatment of various diseases, including cancer, neurodegenerative diseases, and behavioral disorders.

One of the potential strategies for targeting ARHGEF39 is the use of small molecules that can modulate the activity of the protein. The use of small molecules that can modulate the activity of ARHGEF39 may provide new therapeutic options for the treatment of various diseases, including cancer, neurodegenerative diseases, and behavioral disorders.

ARHGEF39 as a biomarker

The expression of ARHGEF39 has been shown to be associated with the regulation of GPCR signaling pathway and has been implicated in the regulation of neurotransmission. Therefore, the expression of ARHGEF39 may be used as a biomarker for the diagnosis and monitoring of various neurological and psychiatric disorders, including cancer, neurodegenerative diseases, and behavioral disorders.

The identification of ARHGEF39 as a potential drug target and biomarker suggests that further research is needed to determine the molecular mechanisms underlying its involvement in the regulation of GPCR signaling pathway and its association with various diseases. The development of small molecules that can modulate the activity of ARHGEF39 may provide new therapeutic options for the treatment of

Protein Name: Rho Guanine Nucleotide Exchange Factor 39

Functions: Promotes cell proliferation

The "ARHGEF39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets